On March 27, 2023 TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), reported a clinical update on survival of newly diagnosed glioblastoma patients in the GLORIA expansion arm evaluating NOX-A12, TME Pharma’s CXCL12 inhibitor, in combination with standard of care radiotherapy and anti-VEGF, bevacizumab (Press release, TME Pharma, MAR 27, 2023, View Source [SID1234629404]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

After 12 months on study (median), 83% of patients (5 of 6) are still alive. With treatment or follow-up for these patients continuing, median overall survival (mOS) has not yet been reached. The 12-month timepoint is an important landmark for assessment since it exceeds the expected survival of approximately 10 months for patients with MGMT unmethylated tumors and incomplete resection1.

"We are pleased to see that data emerging from the expansion arm with NOX-A12 and bevacizumab continue to support our approach. With this trend, we expect NOX-A12 in combination with bevacizumab to outperform the treatment with NOX-A12 alone, for which we reported a median overall survival of 12.7 months. We will continue to provide clinical updates as the data mature and look forward to reporting updated survival data around the 15-month timepoint when we target a presentation at an international scientific congress," said Aram Mangasarian, CEO of TME Pharma.